What Pfizer, Trump, and consumers got out of a surprising deal– and what they didn’t

After months of pledging he would get pharmaceutical companies to lower their prices, President Trump can now say that he pressed the CEO of a major drug maker, Pfizer, to back down on a series of price hikes. However, none of it might make any difference in the amount they pay for their prescription drugs, analysts say. Pfizer’s prices will likely go right back up at the end of the year.
Faculty Associate Gerard Anderson is quoted.

Click to read